Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Gisbert

Showing results (291-300 of 317) with videos related to

Pageof 32
Sort By:
Alimentary Pharmacology & Therapeutics|December 7, 2011
Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre studyM Chaparro, P Burgueño, E Iglesias, et al.
Journal of Crohn'S & Colitis|September 11, 2013
Disease severity in familial cases of IBDM Andreu, L Márquez, E Domènech, et al.
Biochemical Pharmacology|September 25, 2016
Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximabB Hernández-Breijo, M Chaparro, D Cano-Martínez, et al.
Digestive Diseases and Sciences|September 13, 2013
Health care costs of complex perianal fistula in Crohn's diseaseM Chaparro, C Zanotti, P Burgueño, et al.
Mucosal Immunology|May 11, 2018
Human intestinal pro-inflammatory CD11c<sup>high</sup>CCR2<sup>+</sup>CX3CR1<sup>+</sup> macrophages, but not their tolerogenic CD11c<sup>-</sup>CCR2<sup>-</sup>CX3CR1<sup>-</sup> counterparts, are expanded in inflammatory bowel diseaseD Bernardo, A C Marin, S Fernández-Tomé, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2015
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON studyJ Molina-Infante, A J Lucendo, T Angueira, et al.
Inflammatory Bowel Diseases|May 28, 2011
Long-term durability of response to adalimumab in Crohn's diseaseM Chaparro, J Panés, V García, et al.
Alimentary Pharmacology & Therapeutics|July 17, 2013
The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant womenN Pedersen, A Bortoli, D Duricova, et al.
Gut|June 26, 2010
Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapyC Loras, J P Gisbert, M Mínguez, et al.
Alimentary Pharmacology & Therapeutics|February 24, 2015
Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatmentsJ P Gisbert, M Romano, A G Gravina, et al.
Pageof 32

Showing results (291-300 of 317) with videos related to

Sort By:
Pageof 32
Alimentary Pharmacology & Therapeutics|December 7, 2011
Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre studyM Chaparro, P Burgueño, E Iglesias, et al.
Journal of Crohn'S & Colitis|September 11, 2013
Disease severity in familial cases of IBDM Andreu, L Márquez, E Domènech, et al.
Biochemical Pharmacology|September 25, 2016
Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximabB Hernández-Breijo, M Chaparro, D Cano-Martínez, et al.
Digestive Diseases and Sciences|September 13, 2013
Health care costs of complex perianal fistula in Crohn's diseaseM Chaparro, C Zanotti, P Burgueño, et al.
Mucosal Immunology|May 11, 2018
Human intestinal pro-inflammatory CD11c<sup>high</sup>CCR2<sup>+</sup>CX3CR1<sup>+</sup> macrophages, but not their tolerogenic CD11c<sup>-</sup>CCR2<sup>-</sup>CX3CR1<sup>-</sup> counterparts, are expanded in inflammatory bowel diseaseD Bernardo, A C Marin, S Fernández-Tomé, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2015
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON studyJ Molina-Infante, A J Lucendo, T Angueira, et al.
Inflammatory Bowel Diseases|May 28, 2011
Long-term durability of response to adalimumab in Crohn's diseaseM Chaparro, J Panés, V García, et al.
Alimentary Pharmacology & Therapeutics|July 17, 2013
The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant womenN Pedersen, A Bortoli, D Duricova, et al.
Gut|June 26, 2010
Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapyC Loras, J P Gisbert, M Mínguez, et al.
Alimentary Pharmacology & Therapeutics|February 24, 2015
Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatmentsJ P Gisbert, M Romano, A G Gravina, et al.
Pageof 32